secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acurx Pharmaceuticals, Inc. (ACXP)
CIK:        0001736243
Form:       8-K
Filed at:   2025-07-17T23:59:59+00:00
Accession:  0001104659-25-068659
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Acurx shareholders approve reverse split, equity plan increase, and director elections at annual meeting
--------------------------------------------------------------------------------

- All six proposals passed at July 17 meeting; 74.38% of shares represented.
- Reverse stock split authorized at ratio 1:10 to 1:30; board to set timing and exact ratio.
- 2021 Equity Plan share reserve increased from 177,448 to 2,677,448 shares.
- Directors Sailer and Harrison re-elected; auditor CohnReznick ratified; warrant exercise and ELOC approved for Nasdaq compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736243/000110465925068659/0001104659-25-068659-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736243/000110465925068659/tm2521097d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-068659

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer